| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.82B | 2.11B | 2.19B | 2.39B | 2.11B | 2.02B |
| Gross Profit | 534.00M | 618.00M | 668.00M | 830.00M | 670.00M | 599.00M |
| EBITDA | -528.00M | 303.00M | 457.00M | 509.00M | 448.00M | -254.00M |
| Net Income | -844.00M | 169.00M | 178.00M | 927.00M | 220.00M | -508.00M |
Balance Sheet | ||||||
| Total Assets | 4.62B | 5.64B | 5.94B | 6.21B | 6.61B | 6.88B |
| Cash, Cash Equivalents and Short-Term Investments | 207.00M | 300.00M | 417.00M | 646.00M | 210.00M | 454.00M |
| Total Debt | 1.49B | 1.47B | 1.46B | 1.38B | 2.10B | 1.99B |
| Total Liabilities | 2.73B | 2.78B | 2.84B | 2.99B | 3.86B | 3.84B |
| Stockholders Equity | 1.89B | 2.87B | 3.10B | 3.22B | 2.75B | 3.04B |
Cash Flow | ||||||
| Free Cash Flow | 116.00M | 274.00M | 73.00M | -326.00M | 455.00M | 70.00M |
| Operating Cash Flow | 200.00M | 411.00M | 243.00M | -213.00M | 560.00M | 203.00M |
| Investing Cash Flow | -63.00M | -51.00M | -109.00M | 1.56B | -381.00M | 8.00M |
| Financing Cash Flow | -231.00M | -479.00M | -371.00M | -896.00M | -426.00M | 9.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $2.67B | 29.53 | 36.39% | 1.90% | 4.98% | 30.84% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
58 Neutral | $2.39B | ― | -0.64% | 1.42% | 0.08% | -107.33% | |
54 Neutral | $2.29B | ― | -34.45% | 3.29% | -13.67% | ― | |
49 Neutral | $1.89B | ― | -0.09% | 2.13% | -4.49% | -100.80% | |
48 Neutral | $1.74B | ― | -38.91% | ― | -13.39% | 88.25% | |
46 Neutral | $1.88B | ― | -69.74% | 4.91% | 2.12% | -579.74% |
Ashland Global Holdings, Inc. is a global additives and specialty ingredients company that operates in high-quality, consumer-focused markets such as pharmaceuticals, personal care, and architectural coatings. The company recently released its fourth-quarter fiscal 2025 earnings report, highlighting a disciplined approach to navigating challenging market conditions.
Ashland Global Holdings, Inc. recently held its earnings call, demonstrating a resilient performance amidst macroeconomic challenges. The company successfully maintained margins and achieved expected EBITDA, despite experiencing sales declines due to portfolio optimization. Notable successes were seen in the Life Sciences and Personal Care sectors, although challenges persist in the Intermediates segment and coatings demand. Strong cash generation and liquidity were highlighted, but higher tax rates and delayed optimization benefits pose ongoing challenges.
Ashland Inc. reported its fourth-quarter fiscal 2025 results, showing a sales decline to $478 million, down eight percent from the previous year, primarily due to Portfolio Optimization initiatives. Despite challenging market conditions, Ashland maintained strong margins and delivered consistent revenue and EBITDA, with growth in Personal Care and Life Sciences segments. The company received a $103 million tax refund related to the Nutraceuticals divestiture, strengthening its financial position. Ashland’s strategic focus on cost management and portfolio alignment positions it for future profit growth.
The most recent analyst rating on (ASH) stock is a Hold with a $60.00 price target. To see the full list of analyst forecasts on Ashland stock, see the ASH Stock Forecast page.
On September 16, 2025, Sergio Pedreiro resigned from Ashland, Inc.’s Board of Directors, including his roles on the Compensation Committee and as Chair of the Audit Committee, effective September 30, 2025. His resignation led to a reduction in the Board’s size from nine to eight members, and it was clarified that his departure was not due to any disagreements with the company’s practices.
The most recent analyst rating on (ASH) stock is a Hold with a $52.00 price target. To see the full list of analyst forecasts on Ashland stock, see the ASH Stock Forecast page.